Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. (December 2021)

• Record Type: Journal Article
• Authors: Hsia, Judith; Kavanagh, Sarah T; Hopley, Charles W; Baumgartner, Iris; Berger, Jeffrey S; Fowkes, Gerry R; Jones, W Schuyler; Mahaffey, Kenneth W; Norgren, Lars; Patel, Manesh R; Rockhold, Frank; Blomster, Juuso; Katona, Brian G; Hiatt, William R; Bonaca, Marc P
• Is Part Of: Vascular medicine. Volume 26:Number 6(2021)
• Page Start: 608
• Page End: 612
• Publication Date: 2021-12
• Subjects: anemia therapy -- antiplatelet therapy -- chronic kidney disease (CKD) -- peripheral artery disease (PAD); Blood-vessels -- Diseases -- Periodicals; Peripheral vascular diseases -- Periodicals; Vascular Diseases -- Periodicals; Vaisseaux sanguins -- Maladies -- Périodiques; Maladies vasculaires périphériques -- Périodiques; 616.13
• DOI: 10.1177/1358863X211017641
• Languages: English
• ISSNs: 1358-863X

Abstract

Patients with chronic kidney disease may develop new or more severe anemia when treated with antiplatelet agents due to blood loss in conjunction with impaired erythropoiesis. Because anemia independently predicts limb amputation and mortality among patients with peripheral artery disease (PAD), we evaluated the relationship between estimated glomerular filtration rate (eGFR) and hemoglobin (Hb) levels in the EUCLID trial in which patients with symptomatic PAD were randomized to ticagrelor or clopidogrel. At baseline, 9025, 1870, and 1000 patients had eGFR ⩾ 60, 45–59, and < 45 mL/min/1.73 m 2, respectively. The mean fall in Hb during the trial was 0.46 ± 1.68 g/dL and did not differ by baseline eGFR category, although Hb fall ⩾ 10% was more frequent among patients with lower eGFR ( p for trend < 0.0001). On-study treatment with iron, erythropoiesis-stimulating agents, and/or red blood cell transfusion was reported for 479 (5.3%), 165 (8.8%), and 129 (12.9%) patients in the three eGFR categories, respectively ( p for trend < 0.0001). After adjustment for baseline and post-randomization effects, those not receiving anemia treatment had a smaller reduction in Hb from baseline than those receiving anemia treatment ( p < 0.0001). Other determinants of Hb reduction included absence of on-study myocardial infarction, coronary or peripheral revascularization, residence outside North America, male sex, and baseline eGFR. We conclude that among patients with PAD treated with P2Y12 inhibitors, lower baseline eGFR was associated with a greater reduction in Hb.ClinicalTrials.gov Identifier: NCT01732822